Patents Examined by Zachary C. Tucker
-
Patent number: 7405295Abstract: Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.Type: GrantFiled: June 4, 2004Date of Patent: July 29, 2008Assignee: CGI Pharmaceuticals, Inc.Inventors: Kevin S. Currie, Robert W. DeSimone, Scott A. Mitchell, Douglas A. Pippin, James W. Darrow, Xiaobing Qian, Mark Velleca, Dapeng Qian
-
Patent number: 7399766Abstract: The present invention provides a pyrazinoylguanidine compound represented by formula (I): where the structural variables are as defined herein. The compounds are useful for promoting hydration of mucosal surfaces.Type: GrantFiled: August 18, 2004Date of Patent: July 15, 2008Assignee: Parion Sciences, Inc.Inventor: Michael R. Johnson
-
Patent number: 7393848Abstract: Compounds of Formula I and all pharmaceutically acceptable forms thereof, are described herein. The variables R1, R2, R3, Z2, and Q, shown in Formula I are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.Type: GrantFiled: June 30, 2004Date of Patent: July 1, 2008Assignee: CGI Pharmaceuticals, Inc.Inventors: Kevin S. Currie, Robert W. DeSimone, Scott A. Mitchell, Douglas A. Pippin
-
Patent number: 7390907Abstract: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, dType: GrantFiled: September 30, 2004Date of Patent: June 24, 2008Assignee: Amgen Inc.Inventors: Ning Chen, Thomas Nixey, Mark H. Norman
-
Patent number: 7388013Abstract: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.Type: GrantFiled: May 27, 2005Date of Patent: June 17, 2008Assignee: Parion Sciences, Inc.Inventors: Michael R. Johnson, Bruce F. Molino, Jianzhong Zhang, Bruce Sargent
-
Patent number: 7388017Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.Type: GrantFiled: June 27, 2003Date of Patent: June 17, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer
-
Patent number: 7384980Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.Type: GrantFiled: August 10, 2005Date of Patent: June 10, 2008Assignee: Schwarz Pharma AGInventors: Claus Meese, Bengt Sparf
-
Patent number: 7375095Abstract: For extending the uses of a compound represented by Chemical formula 1, the object of the present invention is to provide a derivative of cyclic tetrasaccharide whose physicochemical properties are changed from those of cyclic tetrasaccaride, a composition comprising the same, and a process for producing the same. The present invention solves the above object by providing a derivative of cyclic tetrasaccharide, which is produced by the steps of reacting a compound represented by Chemical formula 1 with a reactive reagent and substituting one ore more hydroxyl groups with substituents except hydroxyl group and O-glycosyl group; a composition comprising the same; and a process for producing the derivative of cyclic tetrasaccharide.Type: GrantFiled: November 19, 2002Date of Patent: May 20, 2008Assignee: Kabashiki Kaisha Hayashibara Seibutsu KagakuInventors: Kazuyuki Oku, Naoki Kudo, Shigeharu Fukuda
-
Patent number: 7375107Abstract: The present invention provides compound represented by formula (I): where the structural variables are defined herein. The compounds function as sodium channel blockers and may be used to treat a variety of respiratory conditions.Type: GrantFiled: August 18, 2004Date of Patent: May 20, 2008Assignee: Parion Sciences, Inc.Inventor: Michael R. Johnson
-
Patent number: 7368451Abstract: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.Type: GrantFiled: August 26, 2005Date of Patent: May 6, 2008Assignee: Parion Sciences, Inc.Inventors: Michael R. Johnson, Bruce F. Molino, Jianzhong Zhang, Bruce Sargent
-
Patent number: 7368450Abstract: The present invention relates to compounds represented by formula (I): in which at least one of R3 and R4 is a group represented by formula (A): where the structural variables are defined herein. The compounds are useful for blocking sodium channels.Type: GrantFiled: April 21, 2004Date of Patent: May 6, 2008Assignee: Parion Sciences, Inc.Inventor: Michael R. Johnson
-
Patent number: 7368447Abstract: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.Type: GrantFiled: August 26, 2005Date of Patent: May 6, 2008Assignee: Parion Sciences, Inc.Inventors: Michael R. Johnson, Bruce F. Molino, Jianzhong Zhang, Bruce Sargent
-
Patent number: 7365194Abstract: A dimer of phenazine-1-carboyxlic acid natural products from fluorescent pseudomonad bacterium and a method of preparing a dimer of phenazine-1-carboxylic acid natural product are disclosed herein. The method comprises growing the bacterium in a water based liquid medium under favorable pH and temperature with continuous agitation, extracting the dimer of phenazine-1-carboyxlic acid natural product from the medium by centrifugation using organic solvents, filtering the resultant emulsion to separate the aqueous layer in a separation funnel, isolating the crude dimer of phenazine-1-carboyxlic acid natural product from the organic layer by evaporating the organic solvent, and purifying the dimer of phenazine-1-carboxylic acid natural product by chromatography.Type: GrantFiled: July 9, 2004Date of Patent: April 29, 2008Assignee: Pondicherry University and Department of BiotechnologyInventors: Natarajan Sakthivel, Radhakrishnan Sunish Kumar
-
Patent number: 7365085Abstract: Disclosed is a compound having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.Type: GrantFiled: March 26, 2003Date of Patent: April 29, 2008Assignee: SmithKline Beecham CorporationInventors: Ajita Bhat, John Jeffrey McAtee, Scott K. Thompson, James S. Frazee, Lara S. Kallander, Chun Ma, Joseph Marino, Michael J. Neeb, Robert A. Stavenger
-
Patent number: 7351807Abstract: Dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions.Type: GrantFiled: July 3, 2001Date of Patent: April 1, 2008Assignee: Mallinckrodt Inc.Inventors: Raghavan Rajagopalan, Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow
-
Patent number: 7351709Abstract: The present invention relates to estrogen receptor ligands, and compounds and methods for treating diseases associated with excessive estrogen receptor activity. Compound of the formula I are disclosed: wherein W is O or (CR8)2, and R1 to R8, Y, and m are defined as defined herein.Type: GrantFiled: June 8, 2005Date of Patent: April 1, 2008Assignee: WyethInventors: Paige Erin Mahaney, Michael Byron Webb, Fei Ye, Joseph Peter Sabatucci
-
Patent number: 7345044Abstract: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.Type: GrantFiled: October 31, 2005Date of Patent: March 18, 2008Assignee: Parion Sciences, Inc.Inventor: Michael R. Johnson
-
Patent number: 7345038Abstract: An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound of formula I, pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression, wherein formula I is or a pharmaceutically acceptable salt or thereof, wherein Z is wherein Y is methylene; X is oxygen; n is 0; R1 and R2 are each hydrogen or halogen; and R3 and R4 together with the nitrogen atom to which they are attached form i) a saturated non-aromatic 3 to 7 membered monocyclic ring, said ring i) being unsubstituted or substituted or substituted with one or more (C1–C4)alkyl, (C1–C4)alkoxy(C1–C4)alkyl, or hydroxy groups.Type: GrantFiled: March 12, 2004Date of Patent: March 18, 2008Assignee: Pfizer, IncInventors: Gene Michael Bright, Michael A. Brodney, Bishop Wlodecki
-
Patent number: 7345172Abstract: In accordance with the present invention there is provided a new class of sterically demanding metallo-intercalators. These compounds intercalate between bases in a duplex polynucleotide, but only where the bases are not fully complementary, for example, where there is a base-pair mismatch. The compounds are sufficiently sterically demanding that intercalation between bases in fully complementary duplexes does not occur to a significant degree. These mismatch intercalators are useful for detecting DNA and RNA defects, for diagnosing disorders characterized by the presence or increase in DNA and/or RNA defects, and for treating such disorders. Further, the compounds are capable of catalyzing photolytic cleavage of nucleic acids at relatively long wavelengths, and under normal sunlight.Type: GrantFiled: October 26, 2004Date of Patent: March 18, 2008Assignee: Calfornia Institute of TechnologyInventors: Jacqueline K. Barton, Henrik Junicke
-
Patent number: 7342019Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which R1 and R2 independently represent: a C1-6alkyl group; an optionally substituted (amino)C1-4alkyl-group; an optionally substituted non-aromatic C3-15carbocyclic group; a (C3-12cycloalkyl)C1-3alkyl-group; a group —(CH2)r(phenyl)s in which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by Z; naphthyl; anthracenyl; an optionally substituted saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; 1-adamantylmethyl; a group —(CH2)t Het in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted and Het represents an optionally substituted aromatic heterocycle; or R1 represents H and R2 is as defined above; or R1 and R2 together with the nitrogen atom to which they are attaType: GrantFiled: December 18, 2002Date of Patent: March 11, 2008Assignee: AstraZeneca ABInventors: Anna Ingrid Kristina Berggren, Stig Jonas Boström, Stig Thomas Elebring, Peter Greasley, Emma Terricabras, Johan Michael Wilstermann